Goldman bearish on Gilead, sees 10% downside risk;
Post# of 145194
![](/assets/46931549/no_avatar_available_thumb.jpg)
"Analyst Terence Flynn cites the looming loss of patent exclusivity for Truvada and Atripla. He also mentions that Biktarvy can only protect about half of the company's $16B HIV franchise from generic competition."
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)